+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: Differentiation from progressive supranuclear palsy



Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: Differentiation from progressive supranuclear palsy



Acta Neuropathologica 90(1): 37-43



Corticobasal degeneration (CBD) is a rare, progressive neurological disorder characterized by widespread neuronal and glial accumulation of abnormal tau protein. Using immunohistochemistry we analyzed tau epitope expression and phosphorylation state in CBD and compared them to cytoskeletal changes in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP). Epitopes spanning the entire length of the tau protein were present in CBD inclusions. An antibody against the alternatively spliced exon 3 did not recognize cytoskeletal lesions in CBD, but did in AD and PSP. Tau epitopes from each region of the molecule were present in cytoskeletal inclusions in CBD, including gray matter astrocytic plaques, gray and white matter threads, and oligodendroglial inclusions. As in AD, tau from CBD was highly phosphorylated. Antibodies that recognized phosphorylated tau epitopes reacted with material from CBD in a highly phosphatase-dependent manner. Again, all types of inclusions contained phosphorylated epitopes. We conclude that abnormal tau protein in CBD comprises the entire tau molecule and is highly phosphorylated, but is distinguished from AD and PSP by the paucity of epitopes contained in the alternatively spliced exon 3.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008619511

Download citation: RISBibTeXText

PMID: 7572077

DOI: 10.1007/bf00294457


Related references

Tau epitope display in progressive supranuclear palsy and corticobasal degeneration. Journal of Neurocytology 33(3): 287-295, 2004

Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. Journal of Neurology 246(Suppl. 2): II/6-II/15, 1999

Corticobasal degeneration and progressive supranuclear palsy--differentiation by somatosensory-evoked potentials. No to Shinkei 48(3): 253-257, 1996

An unusual autopsy case of corticobasal degeneration--with special reference to clinicopathological differentiation from progressive supranuclear palsy and slowly progressive aphasia. No to Shinkei 48(6): 559-565, 1996

Corticobasal degeneration: widespread argentophilic threads and glia in addition to neurofibrillary tangles. Similarities of cytoskeletal abnormalities in corticobasal degeneration and progressive supranuclear palsy. Journal of the Neurological Sciences 138(1-2): 66-77, 1996

Progressive supranuclear palsy and corticobasal ganglionic degeneration: differentiation by clinical features and neuroimaging techniques. Journal of Neural Transmission. Supplementum 42: 79-90, 1994

A comparison of tau protein cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neuroscience Letters 259(2): 127-129, 1999

The difference of tau protein isoforms between white matter and cortex in progressive supranuclear palsy and corticobasal degeneration. Society for Neuroscience Abstracts 27(1): 1143, 2001

Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. Journal of the Neurological Sciences 183(1): 95-98, 2001

Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. Molecular Brain Research 104(2): 210-219, 15 August, 2002

Progressive supranuclear palsy and corticobasal degeneration. Bailliere's Clinical Neurology 6(1): 167-185, 1997